2026-01-24 - Analysis Report
### Company Overview
Invesco is a US-based financial services company that specializes in investment management.

### Return Rate Comparison
| Stock | Cumulative Return | Divergence | Relative Divergence |
| --- | --- | --- | --- |
| IVZ | 81.97% | -44.40 | 55.10% |
| VOO | 126.41% | N/A | N/A |

The return rate of IVZ is lower than the return rate of VOO, resulting in a divergence of -44.40.

### Analysis of Alpha, Beta and Cap

| Period | CAGR | MDD | Alpha | Beta | Cap(B) |
| --- | --- | --- | --- | --- | --- |
| 2016-2018 | -30.0% | 36.6% | -43.0% | 1.4 | 7.5B |
| 2017-2019 | -21.0% | 36.6% | -46.0% | 1.2 | 8.0B |
| 2018-2020 | -23.0% | 57.7% | -47.0% | 1.5 | 7.8B |
| 2019-2021 | 58.0% | 57.7% | -8.0% | 1.6 | 10.3B |
| 2020-2022 | 26.0% | 57.7% | 19.0% | 1.6 | 8.0B |
| 2021-2023 | -7.0% | 41.9% | -27.0% | 1.5 | 8.0B |
| 2022-2024 | -13.0% | 35.9% | -42.0% | 1.4 | 7.8B |
| 2023-2025 | 65.0% | 34.8% | -10.0% | 1.5 | 11.7B |

IVZ's cap has fluctuated between 7.5B to 11.7B over different market cycles, with an average beta of 1.4 to 1.6. The alpha is negative in some periods, indicating a relatively poor performance compared to the market.

### Stock Price Fluctuations
| Metric | Value |
| --- | --- |
| Close | $28.40 |
| Last-market | $28.40 |
| 5-day SMA | $28.83 |
| 20-day SMA | $28.02 |
| 60-day SMA | $25.78 |

The current stock price of IVZ is $28.40. The 5-day and 20-day moving averages are $28.83 and $28.02 respectively. The 60-day moving average is $25.78.

### RSI, PPO and Delta_Previous_Relative_Divergence

| Indicator | Value |
| --- | --- |
| RSI | 58.75 |
| PPO | -0.23 |
| MRI | 0.70 |
| Risk Level | Medium |
| Recent | -4.50 (-) |
| 7-day Rank | 112 (+) |
| 7-day Dynamic Expected Return | 49.60 (+) |
| Expected Return (%) | -61.70% |

The RSI indicates IVZ's stock is slightly overbought. The PPO indicates IVZ's stock is slightly oversold. The MRI is 0.70, indicating a medium risk level. The recent relative divergence change is -4.50, indicating a worsening trend. The 7-day dynamic expected return is 49.60, indicating an improving trend.

### Recent News & Significant Events
1. Does RBC’s IVZ Upgrade and QQQ Reclassification Alter Invesco’s Active–Passive Growth Balance? - simplywall.st
2. Invesco: Asset Manager Hits Ceiling Of Fair Value - Seeking Alpha
3. How Invesco Ltd (IVZ) Affects Rotational Strategy Timing - Stock Traders Daily
4. Invesco (IVZ) Stock Trades Up, Here Is Why - The Globe and Mail
5. Assessing Invesco (IVZ) Valuation After RBC Capital’s Outperform Upgrade And QQQ ETF Earnings Tailwind - Yahoo Finance
6. IVZ Stock Upgraded to "Outperform" with Raised Price Target by R - GuruFocus

IVZ has received several positive news articles. Analysts have upgraded IVZ's rating and raised its price target.

### Analyst Opinions

| Analyst Opinions |
| --- |
| Analyst Consensus: Buy |
| Mean (1=StrongBuy~5=Sell): 2.33 (~Buy) |
| Opinions: 11 |
| Target Price (avg/high/low): 30.30 / 35.00 / 24.00 |

### Recent Earnings Analysis

| Quarter | EPS | Revenue |
| --- | --- | --- |
| 2025-11-04 | 0.67 | $1.64B |
| 2025-08-01 | -0.03 | $1.52B |
| 2025-04-28 | 0.38 | $1.53B |
| 2024-10-29 | 0.12 | $1.52B |
| 2025-11-04 | 0.12 | $1.52B |

Earnings per share (EPS) fluctuates between 0.12 and 0.67 over different quarters. Revenue fluctuates between $1.52B and $1.64B.

### Financial Information
#### Revenue and Profitability

| Quarter | Revenue | Profit Margin |
| --- | --- | --- |
| 2025-09-30 | $1.64B | 34.17% |
| 2025-06-30 | $1.52B | 33.28% |
| 2025-03-31 | $1.53B | 36.33% |
| 2024-12-31 | $1.59B | 37.83% |
| 2024-09-30 | $1.52B | 25.76% |

#### Capital and Profitability

| Quarter | Equity | ROE |
| --- | --- | --- |
| 2025-09-30 | $14.01B | 2.47% |
| 2025-06-30 | $13.87B | 1.47% |
| 2025-03-31 | $14.70B | 1.57% |
| 2024-12-31 | $14.56B | 1.84% |
| 2024-09-30 | $14.75B | 0.77% |

Equity fluctuates between $13.87B and $14.75B over different quarters. Return on equity (ROE) fluctuates between 0.77% and 2.47%.

### Comprehensive Analysis

IVZ's recent performance is affected by various analysts' upgrades, a positive news environment, and fluctuating revenue and earnings per share (EPS). The RSI and PPO indicators indicate a slight oversold condition. The MRI indicates a medium risk level. IVZ's cap has fluctuated between 7.5B to 11.7B over different market cycles, with an average beta of 1.4 to 1.6.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.